中国中药杂志

2019, v.44(14) 2896-2901

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

中成药上市后安全性医院集中监测技术规范
Technical specifications for hospital-based intensive monitoring of post-marketing Chinese patent medicine

谢雁鸣;廖星;姜俊杰;张允岭;马融;朱明军;詹思延;刘建平;刘健;温泽淮;杨忠奇;何燕;李学林;
XIE Yan-ming;LIAO Xing;JIANG Jun-jie;ZHANG Yun-ling;MA Rong;ZHU Ming-jun;ZHAN Si-yan;LIU Jian-ping;LIU Jian;WEN Ze-huai;YANG Zhong-qi;HE Yan;LI Xue-lin;Centre for Evidence-Based Traditional Chinese Medicine,Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences;Xiyuan Hospital,China Academy of Chinese Medical Sciences;the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine;the First Affiliated Hospital of Henan University of Traditi

摘要(Abstract):

2013年国家食品药品监督管理总局药品安全监管司下发了有关生产企业药品重点监测工作的指南,鼓励企业开展重点监测工作。随后,有关中成药上市后安全性医院集中监测的研究日渐增多,掀起了中成药安全性评价研究的一股热潮。然而,纵观目前该领域现状来看,医院集中监测的开展缺乏规范,如设计不合理、漏报、过程质量控制不严格、不良反应判读不规范等,因此,制定相关技术规范非常必要。该规范参照国际药品上市后安全性监测模式和先进设计理念与方法,并在我国相关法律法规和技术文件指导的框架下,结合中成药自身特点以及我国的实际情况,制定而成。目的在于通过实施这类设计的监测获得中成药不良反应发生率、类型、程度及临床表现,发现新的不良反应风险信号,确定危险因素,为制定风险管控计划提供依据。该技术规范已通过中华中医药学会的审核,并被发布,编号T/CACM011-2016。
In 2013,China pharmaceutical regulatory department issued guiduance on postmarketing drug safety monitoring for industry. It aimed to encourage industry to carry out postmarketing drug safety monitoring including hospital-based intensive monitoring of postmarketing Chinese patent medicine. Subsequently,more and more such kind of studies have been performed all over China. However,in view of the current situation in this field,the development of hospital-based intensive monitoring of postmarketing Chinese patent medicine lacks standardization,such as unreasonable design,omission of reports about adverse drug reactions,inadequate process of quality control,non-standardized interpretation of adverse reactions,etc. Therefore,it is necessary to formulate relevant technical specifications to guide this area. The developing of this technical specification refered to the international post-marketing safety monitoring model and advanced design concepts and methods. We developed it under the guidance of relevant laws,regulations and technical documents in China. Meanwhile the characteristics of Chinese patent medicines and the real situation in this area were considered. The aim of this technical specification is to obtain the incidence,type,degree and clinical manifestation of adverse drug reactions of Chinese patent medicines,to find new risk signals of adverse reactions,to identify risk factors,and to provide a basis for the formulation of risk management and control plans. This specification has been approved by China association of Chinese medicine which is numbered T/CACM011-2016.

关键词(KeyWords): 标准;中成药;上市后安全性;医院集中监测;技术规范
standards;Chinese patent medicine;Chinese patent medicine postmarketing safety evaluating;hospital-based intensive monitoring;technical specifications

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划项目(2018YFC1707400);; 中华中医药学会团体标准(T/CACM011-2016);; 国家自然科学基金面上项目(81774159);国家自然科学基金青年基金项目(81603517)

作者(Author): 谢雁鸣;廖星;姜俊杰;张允岭;马融;朱明军;詹思延;刘建平;刘健;温泽淮;杨忠奇;何燕;李学林;
XIE Yan-ming;LIAO Xing;JIANG Jun-jie;ZHANG Yun-ling;MA Rong;ZHU Ming-jun;ZHAN Si-yan;LIU Jian-ping;LIU Jian;WEN Ze-huai;YANG Zhong-qi;HE Yan;LI Xue-lin;Centre for Evidence-Based Traditional Chinese Medicine,Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences;Xiyuan Hospital,China Academy of Chinese Medical Sciences;the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine;the First Affiliated Hospital of Henan University of Traditi

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享